Atlas Trials

Poorly Differentiated Malignant Neuroendocrine Carcinoma

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Poorly Differentiated Malignant Neuroendocrine Carcinoma

RecordFirmDate
Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (NCT02113800)AIO-Studien-gGmbH2015-08-01

Track Poorly Differentiated Malignant Neuroendocrine Carcinoma automatically

Every clearance here is in the API, with alerts when new ones post.